title: [Multi-modal serial therapy for primary liver cancer in senile patients: a report of 153 cases].
abstract: OBJECTIVE
  To study the feasibility and validity of multi-modal serial therapy for primary liver cancer in senile patients.
  
  
  METHODS
  153 senile primary liver cancer patients (>or= 60 years) were given multi-modal serial therapy from June 1993 to December 2000. Hepatectomy was performed in 37, deep cryosurgery in 32 and non-operative therapy in 84 (intervention as chief therapy in 81, combined local and intervention therapy in 3). The multi-course intervention therapy was given postoperatively in hepatectomy and cryosurgery groups, while bioimmunotherapy and traditional Chinese medicine were used in all groups.
  
  
  RESULTS
  The 1-, 3- and 5-year survival rates in the hepatectomy group were 78.4%, 46.4% and 35.7%, without operative mortality. The 1- and 3- and 5-year year survival rates in the cryosurgery group were 64.5%, 40.9% and 25.0% with mortality of 3.1%. Among patients with non-operative therapy, the 1- and 3- and 5-year year survival rates in intervention group were 47.5%, 23.5% and 4.3%. The operative mortality was 1.2%. The 3 patients who received combined local and intervention therapy have survived for 2.5, 3.8 and 7.1 years.
  
  
  CONCLUSIONS
  Multi-modal serial therapy with surgical treatment as the chief means, being precise in the effect and good in safety, is feasible and valid for primary liver cancer in senile patients.
authors.affiliation: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Jing-an
authors.initials: JA
authors.lastname: Rui
authors.forename: Shao-bin
authors.initials: SB
authors.lastname: Wang
authors.forename: Shu-guang
authors.initials: SG
authors.lastname: Chen
authors.forename: Qiang
authors.initials: Q
authors.lastname: Qu
authors.forename: Xue
authors.initials: X
authors.lastname: Wei
authors.forename: Kai
authors.initials: K
authors.lastname: Han
authors.forename: Ning
authors.initials: N
authors.lastname: Zhang
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Zhao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005240:Feasibility Studies; D005260:Female; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents